CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)

Impact Biomedical Inc (NYSE: IBO) announced a 1 for 12.62 reverse stock split effective September 23, 2026, to support its proposed merger with Zoar Limited. The merger exchange ratio was corrected to 1 share of Zoar for every 1 share of Impact stock (post-split). Upon completion, the combined entity will focus on developing and supplying Active Pharmaceutical Ingredients for special therapeutic areas.

09/14/2026, 9:26 PM • GlobeNewswire

ImPact Biotech Presents Updated Data from Phase 1 Trial of Padeliporfin VTP in LA-PDAC and Phase 3 ENLIGHTED Trial in LG-UTUC at ASCO 2026

ImPact Biotech announced updated clinical trial data for Padeliporfin VTP, a vascular-targeted photodynamic therapy. In the Phase 1 LA-PDAC trial, 71% of patients (5/7) achieved successful surgical resection with a well-tolerated safety profile. The Phase 3 ENLIGHTED trial in LG-UTUC showed 70% complete response rates with 85.7% of patients sustaining responses for at least 12 months. The company plans to submit an NDA for LG-UTUC in 2027 and is exploring potential accelerated registrational pathways for LA-PDAC.

05/30/2026, 10:00 AM • GlobeNewswire

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

ImPact Biotech announced updated Phase 3 ENLIGHTED trial results for Padeliporfin VTP in low-grade upper tract urothelial cancer, showing 70% complete response rate in 72 evaluable patients and 85.7% durability at 12 months. The treatment demonstrated a consistent safety profile with mostly mild to moderate adverse events. Topline data expected later in 2026 with regulatory submission planned for 2027.

05/16/2026, 7:00 AM • GlobeNewswire

Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans

Impact BioMedical Inc. (NYSE American: IBO) received a 'going concern' qualification in its 2025 10-K audit opinion from Grassi & Co., CPAs, indicating substantial doubt about the company's ability to continue operations. Despite this financial concern, the company continues pursuing a strategic merger with Dr. Ashley's Ltd., projected to close by July 1, 2026.

04/03/2026, 1:52 PM • GlobeNewswire

Impact Biomedical (IBO) Stock Jumps Over 86% After Hours — Here's Why

Impact Biomedical (IBO) shares surged 86.28% in after-hours trading to $0.77 following an SEC filing that disclosed amendments to its pending merger with Dr Ashleys Bio Labs Limited. The merger agreement was extended from March 31 to July 1, 2026, with revised share allocations. Dr Ashleys will issue 169.5 million shares (94.20% of total), while parent company DSS will receive 53,000 shares with potential for 75,000 additional shares if funding obligations are met.

03/04/2026, 11:38 PM • Benzinga

DSS, Inc.'s Subsidiary, Impact BioMedical Inc., Announces Strategic Merger

DSS, Inc. announced that its subsidiary, Impact BioMedical Inc., has entered into a definitive merger agreement with Dr. Ashleys Limited, a global pharmaceutical company. The transaction will result in a newly formed combined entity traded on the NYSE American under the name 'Dr Ashleys Limited'.

06/24/2025, 8:30 AM • Benzinga